Skip to content

Warenkorb

Der Warenkorb ist leer.

Gesamt (exkl. MwSt.) £0,00
Warenkorb überprüfen & bezahlen
Antikörper

Phospho-PKC (pan) (Clone: gamma Thr514) (Clone: PF4) rabbit mAb

Produktgrößen
20 µl
£631,00
12-4341-20UL
200 µl
£1021,00
12-4341-200UL
Über dieses Produkt
SKU:
12-4341
Zusätzliche Namen:
Protein kinase C gamma type; PRKCG; PKCG
translate.label.attr.clone:
PKCgT514-PF4
Klonalität:
Monoclonal
Konjugat:
Unconjugated
Weitere Details:
Protein Kinase (PKC) is a 12 member family of serine/threonine kinases termed conventional or classical(a b;g); novel (d ;e ;andq ); atypical (z ;l) and PKN and PKC-related (PKN1; PKN2 and PKN3) playing significant role in several signaling processes involved in physiological and pathological setting (1). PKC activation translates into gene expression modulation; cell division; migration; proliferation; differentiation; and cell survival and apoptosis (2).PKC members are classified based on their distinct cofactor requirements and the extent of homology between their regulatory elements (3;4). PKCalpha;beta I;beta II; andgamma constitute the conventional PKC isoforms; characterized by the presence of two cysteine-rich zinc finger domains; C1a and C1b (5;6) which bind to diacylglycerol (DAG) and phosphatidylserine (PS) (7). In addition; PKC contains a C2 domain; responsible for binding anionic phospholipids like phosphatidylinositol bisphosphate (PIP2) in a Ca2+-dependent manner (8;9). The atypical PKC; PKCzandlshare ATP-binding domain and the catalytic domain with PKC. They contain a single C1 domain that lacks residues necessary for binding DAG (10). Association of PKCg to the membrane enables a conformation that permits phosphoinositide-dependent protein kinase1 (PDK-1) (11) to bind and phosphorylate a site in the activation loop; Thr514. (12;13). Thr514 phosphorylation leads to a conformation change enabling phosphorylation of at two carboxyl-terminal sites namely; the turn motif and hydrophobic motif; as a result of which the fully phosphorylated conventional PKC is released from the membrane; and positioned in the cytoplasm as an inactive form (14;15). Binding of Ca 2+induces low-affinity interaction with the membrane; whereas the membrane imbedded cofactor DAG to PKC results in high-affinity interaction of PKC with the membrane (16).
Format:
Purified
Host:
Rabbit
Immunogen:
A synthetic phospho-peptide corresponding to residues surrounding Thr514 of human phospho PKCg
Isotyp:
Rabbit IgG1k
Reaktivitäten:
Human, Mouse, Rat
Versandbedingungen:
Blue Ice
Lagerbedingungen:
Store at -20[o]C. Avoid repeated freeze and thaw cycles.
Hersteller:
Abeomics
Typ:
Antibodies:Monoclonal Antibody
  • Datenblatt des Herstellers:1.jpg
Fig 2 : Flow cytometric analysis of HT1080 cells; treated with staurosporine and stained with the secondary antibody only as negative control (blue) or treated with staurosporine (red) or untreated (green) using Phospho-PKC (pan) (gamma Thr514) antibody PKCgT514-PF4 at 0.05 µg/mL.
Fig-3: Flow cytometric analysis of Jurkat cells; treated with K252a and stained with the secondary antibody only negative control (blue) or treated with K252a (red) or untreated (green) using Phospho-PKC (pan) (gamma Thr514) antibody PKCgT514-PF4 at 0.1 µg/mL.
Fig-4: Peptide blocking flow cytometric analysis of HT1080 cells secondary antibody only negative control (light blue) or untreated (red) or treated with staurosporine (green) or untreated and blocked with phospho-peptide (black) or treated with staurosporine and blocked with phospho peptide (gold) or untreated and blocked with non-phospho peptide (dark blue) or treated with staurosporine and blocked with non-phospho peptide (purple) using Phospho-PKCg (Thr514) antibody PKCGT514-PF4 at 0.05 µg/m
Fig-4: Peptide blocking flow cytometric analysis of HT1080 cells secondary antibody only negative control (light blue) or untreated (red) or treated with staurosporine (green) or untreated and blocked with phospho-peptide (black) or treated with staurosporine and blocked with phospho peptide (gold) or untreated and blocked with non-phospho peptide (dark blue) or treated with staurosporine and blocked with non-phospho peptide (purple) using Phospho-PKCg (Thr514) antibody PKCGT514-PF4 at 0.05 µg/m
Fig-5: Western blot analysis of C6 cell extract untreated or treated with staurosporine using Phospho-PKC (pan) gamma (Thr514) antibody PKCgT514-PF4 at 0.1 µg/mL.